Personalized mRNA Vaccine Extends Pancreatic Survival

A 16‑patient Phase 1 trial of a personalized mRNA cancer vaccine for operable pancreatic cancer produced durable T‑cell responses and a cluster of long‑term survivors at six‑year follow‑up. Patients had tumor resection, received nine personalized mRNA doses plus standard chemotherapy, and several responders remain alive six years later; larger Phase 2 trials are already underway and parallel KRAS 'off‑the‑shelf' vaccines are in early testing. — If replicated, this could change standard care for pancreatic cancer, drive major biotech investment and manufacturing scale‑up, and force regulators and health systems to plan for personalized vaccine workflows.